Please login to the form below

Ionis

This page shows the latest Ionis news and features for those working in and with pharma, biotech and healthcare.

Alnylam gains key NICE approval for Onpattro

Marketed by Ionis subsidiary Akcea Therapeutics, Tegsedi stole a march over Onpattro when it gained NICE approval in April, but now Alnylam has a matching recommendation from England’s cost watchdog.

Latest news

Twentyeight-Seven raises another $15m for non-coding RNA drugs

the likes of Ionis/Akcea and Alnylam.
Akcea gets first OK for Waylivra in rare triglyceride disorder

The EU is the first market for the new drug. It’s a big win for Akcea, a subsidiary of Ionis, as the US FDA turned down its marketing application for
Speedy approval for Pfizer's Onpattro rival

The drug will represent competition for the two existing ATTR treatments already on the market, Alnylam's Onpattro and Ionis' Tegsedi, even though they currently target different patient sub-types.
Biogen’s tofersen shows promise in slowing down ALS

The drug is another antisense therapy derived from Biogen's alliance with Ionis, and if approved would add to the partners' existing rare disease treatment with a similar mechanism, Spinraza. ... Tofersen is just one of seven candidates licensed by
Lilly invests in antibody oligonucleotides conjugates with Avidity deal

Biogen and Ionis has seen success with their oligonucleotide-based medicines Spinraza, which was approved in the US in 2016 to treat those with spinal muscular atrophy (SMA), a rare neurodegenerative

More from news
Approximately 14 fully matching, plus 27 partially matching documents found.

Latest Intelligence

Where next in Alzheimer’s disease R&D?

The big biotech is testing its own BIIB092 in early Alzheimer’s patients and has an option to develop an Ionis Pharmaceuticals’ antisense drug designed to reduce production of tau in
Deal Watch October 2018

Joint development using SQZ’s cell therapy. platform. $1.375B. Option. Ionis. RNA‐targeted therapeutics for complement mediated. ... RNA‐targeted therapeutic, IONIS‐FB‐LRx targeting Factor. B, for Geographic Atrophy, an advanced form of dry
Alnylam’s big moment: bringing groundbreaking RNAi drugs to Europe

While Onpattro has outshone Ionis’ product in safety and efficacy, analysts see Onpattro’s lack of cardiovascular claims in its US label as a weak point. ... England’s NICE is just beginning its review of Onpattro (in tandem with a review of
The European Medicines Agency: PRIME’d for access?

Since March 2018 Roche, with Ionis, have added another PRIME drug to their portfolio. ... RG6042 (formerly named IONIS-HTTRx) is in development for Huntington’s disease.
Deal Watch February 2017

Ionis has recently received a $75m milestone payment from Bayer having successfully completed a phase II study on IONIS-FXIRx in patients with end-stage renal disease on haemodialysis. ... As part of the agreement Ionis will also expand the collaboration

More from intelligence
Approximately 0 fully matching, plus 8 partially matching documents found.

Featured jobs

Account Director, Healthcare Communications: Salary TBC

Strategic Planner, Healthcare Advertising Agency: Salary TBC

Senior Medical Writer, Healthcare Advertising Agency: £45, 000 – £50, 000

Account Director - Healthcare Advertising - London - 2 DAYS HOME...: £50000 - £70000

FREELANCE Medical Writer (Initial 2/ 3 months term) - London Off...: Excellent Daily Rate

FREELANCE Account Director – Healthcare Advertising – London – 3...: Competitive Daily Rates

Account Director – UK Office: Excellent salary and benefits

Account Director – London based Medical Communications Agency: Excellent Remuneration Package

Account Director - Medical Communications - London / South East: Excellent Salary and Benefits on offer

Senior Account Executive – Account Manager – Healthcare Advertis...: £32000 - £43000 Bonus Benfits

Senior Account Manager > Account Director - London - Medical ...: Salary TBC

Subscribe to our email news alerts

PMHub

Add my company

SEVEN STONES

Seven Stones is a creative, independent healthcare communications agency of movers and thinkers. We've been doing health differently since 1991....

Latest intelligence

Blended Intelligence: Data is the most valued commodity of the modern world. For P&P it's all about the application....
The relevance of patient perspectives to value: Exploring the evolution of patient involvement in health technology assessment, and the role of the patient voice in market access....
How is the NHS Long-term Plan being put into action?: Steve How, Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore some of the changes that have occurred since the plan was published...